RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells target lymphoma after transplant
Disease control OngoingThis study tests a new treatment for people with high-risk B-cell non-Hodgkin lymphoma that has come back. After a stem cell transplant, patients receive genetically modified immune cells designed to recognize and attack cancer cells. The goal is to see if this approach is safe a…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage trial tests a new three-drug combination (ibrutinib, rituximab, and bendamustine) in adults with certain types of non-Hodgkin lymphoma that have come back after prior treatment. The main goal is to find the safest dose of ibrutinib when given with the other two d…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New hope for tough lymphoma: targeted drug shows promise
Disease control OngoingThis study tested a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal was to see how many patients had their tumors shrink or di…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
Engineered immune cells target tough lymphoma after transplant
Disease control OngoingThis early-phase study tests a new immune therapy for people with high-risk or returning non-Hodgkin lymphoma. After a stem cell transplant, patients receive specially modified T-cells designed to find and attack cancer cells. The main goals are to check safety and find the best …
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 05, 2026 12:10 UTC